Dr. Michael Johnson

    Surgical Management of Sub Retinal Hemorrhage

    10/24/2017 12:00:00 AM

    Healthy Living – October 23, 2017
    Michael Johnson, MD – Eastern Maine Medical Center
      Johnson.jpg
    Management of subfoveal hemorrhage in age-related macular degeneration (AMD) is a challenging and difficult situation for the patient and the surgeon. How disheartening to look inside an eye to find a large clot of blood under the fovea, a small depression in the retina of the eye, particularly after other treatments have already been initiated. Such a clot is a sign of submacular hemorrhage and occult choroidal neovascularization (CNV). 

    Even worse is the devastating loss of vision for the patients, who carry an extremely poor prognosis. In this hopeful day of anti-vascular endothelial growth factor (VEGF) therapy, an easy fix for those patients with subretinal bleeds from AMD and devastating visual loss is yet to be found.

    Part of the dilemma of finding a way to improve this condition is that these cases are infrequent. Another major factor in this disease process is time.
    The blood is toxic to the retina and damage occurs early. Those patients whose hemorrhage was less than 14 days old had a twofold chance of visual improvement compared to those whose hemorrhage was 14 to 21 days old. None of the patients with blood under the macula for longer than 21 days improved vision.
     
     Another consideration is that even with successful management of a submacular hemorrhage, the choroidal neovascular membrane and the disease process of AMD is not better. Even after the blood is cleared and the vision returns, patients may have further vision loss from recurrent CNV.

    The debate continues: ethically, what should be done; financially does this make sense; and, in the end, will anything improve visual function?  Of course not all submacular hemorrhages are created equal. They come in all shapes and sizes and depths. The available natural history studies did not classify the extent of hemorrhage in the small-case analysis. Presumably, small thin hemorrhage under the fovea most likely would have a far better prognosis than the dense choroidal hemorrhage with serous retinal detachment.
     
    Treatment Options

    Current possible managements for subretinal hemorrhage include observation, treatments that do not address the damage from the hemorrhage, such as anti-VEGF medication or photodynamic therapy (PDT), and treatments that target removal of hemorrhage from the macula, such as submacular surgical extraction, pneumatic displacement with or without tissue plasminogen activator, lavage with perflurocarbon liquid, and macular translocation.
     

  • Surgical Management of Sub Retinal Hemorrhage 10/24/2017

    Surgical Management of Sub Retinal Hemorrhage 

    Read More

  • New Treatment for Diabetic Retinopathy 09/19/2017

    New Treatment for Diabetic Retinopathy

    Read More

  • Endophthalmitis 08/22/2017

    Endophthalmitis

    Read More

  • Retinal Pigment Epithelial Transplant Geographic Atrophy 05/23/2017

    For years, people were throwing away cells that could bring eyesight to the blind. These dark, blackened cells looked like spots of contamination in the petri dishes in which researchers around the world were carefully nurturing highly purified colonies of human stem cells.

    Read More

  • Retinal Prosthesis 04/25/2017

    Retinal Prosthesis

    Read More

  • Central Serous Retinopathy 01/24/2017

    Central Serous Retinopathy

    Read More

  • Retinal Vein Occlusion 11/15/2016

    Retinal Vein Occlusion

    Read More

  • Optogenetics

    Optogenetics

    Read More